Actively Recruiting
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
Led by Peking University People's Hospital · Updated on 2026-03-03
100
Participants Needed
1
Research Sites
129 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This project aims to innovatively integrate multi-omics data, including plasma metabolomics, radiomics, and cfDNA multi-level information, combined with survival data (e.g., RFS), to establish a novel multidimensional approach for noninvasive postoperative recurrence monitoring in lung cancer using artificial intelligence algorithms. The goal is to develop a new noninvasive recurrence monitoring system for lung cancer.
CONDITIONS
Official Title
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed written informed consent.
- Male or female, aged 18 to less than 85 years.
- Underwent radical resection for pathologic stage IB-IIIA non-small-cell lung cancer.
- Availability of tumor tissue and blood samples at all required time points.
- No pure ground-glass nodule visible on imaging.
- Completed standard neoadjuvant immunotherapy combined with platinum-based chemotherapy.
You will not qualify if you...
- Postoperative pathology showing other than non-small-cell lung cancer such as benign lesions, small-cell carcinoma, metastasis, or inadequate histology.
- Insufficient or poor-quality blood or tissue samples.
- Presence of pure ground-glass nodule on imaging.
- History of any malignancy within the past 5 years.
- Contraindications preventing radical surgical resection.
- Non-radical (R2) surgical resection.
- Pathologic stage IIIB-N3, IIIC, or IV on paraffin sections.
- Refusal or withdrawal of informed consent.
- Any condition considered unsuitable by the investigator, including perioperative blood transfusion or severe psychiatric disorder preventing follow-up.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
K
Kezhong Chen
CONTACT
Y
Yue He
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here